Cargando…

The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort

BACKGROUND: Insulin-like peptide 3 (INSL3) is a constitutive hormone secreted in men by the mature Leydig cells of the testes. It is an accurate biomarker for Leydig cell functional capacity, reflecting their total cell number and differentiation status. OBJECTIVES: To determine the ability of INSL3...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivell, Richard, Heng, Kee, Severn, Katie, Antonio, Leen, Bartfai, Gyorgy, Casanueva, Felipe F., Huhtaniemi, Ilpo T., Giwercman, Aleksander, Maggi, Mario, O’Connor, Daryl B., O’Neill, Terence W., Punab, Margus, Rastrelli, Giulia, Slowikowska-Hilczer, Jolanta, Tournoy, Jos, Vanderschueren, Dirk, Wu, Frederick C. W., Anand-Ivell, Ravinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679513/
https://www.ncbi.nlm.nih.gov/pubmed/36425465
http://dx.doi.org/10.3389/fendo.2022.1016107
_version_ 1784834209066516480
author Ivell, Richard
Heng, Kee
Severn, Katie
Antonio, Leen
Bartfai, Gyorgy
Casanueva, Felipe F.
Huhtaniemi, Ilpo T.
Giwercman, Aleksander
Maggi, Mario
O’Connor, Daryl B.
O’Neill, Terence W.
Punab, Margus
Rastrelli, Giulia
Slowikowska-Hilczer, Jolanta
Tournoy, Jos
Vanderschueren, Dirk
Wu, Frederick C. W.
Anand-Ivell, Ravinder
author_facet Ivell, Richard
Heng, Kee
Severn, Katie
Antonio, Leen
Bartfai, Gyorgy
Casanueva, Felipe F.
Huhtaniemi, Ilpo T.
Giwercman, Aleksander
Maggi, Mario
O’Connor, Daryl B.
O’Neill, Terence W.
Punab, Margus
Rastrelli, Giulia
Slowikowska-Hilczer, Jolanta
Tournoy, Jos
Vanderschueren, Dirk
Wu, Frederick C. W.
Anand-Ivell, Ravinder
author_sort Ivell, Richard
collection PubMed
description BACKGROUND: Insulin-like peptide 3 (INSL3) is a constitutive hormone secreted in men by the mature Leydig cells of the testes. It is an accurate biomarker for Leydig cell functional capacity, reflecting their total cell number and differentiation status. OBJECTIVES: To determine the ability of INSL3 to predict hypogonadism and age-related morbidity using the EMAS cohort of older community-dwelling men. MATERIALS & METHODS: Circulating INSL3 was assessed in the EMAS cohort and its cross-sectional and longitudinal relationships to hypogonadism, here defined by testosterone (T) <10.5nmol/l, and a range of age-related morbidities determined by correlation and regression analysis. RESULTS & DISCUSSION: While INSL3 is an accurate measure of primary hypogonadism, secondary and compensated hypogonadism also indicate reduced levels of INSL3, implying that testicular hypogonadism does not improve even when LH levels are increased, and that ageing-related hypogonadism may combine both primary and secondary features. Unadjusted, serum INSL3, like calculated free testosterone (cFT), LH, or the T/LH ratio reflects hypogonadal status and is associated with reduced sexual function, bone mineral density, and physical activity, as well as increased occurrence of hypertension, cardiovascular disease, cancer, and diabetes. Using multiple regression analysis to adjust for a range of hormonal, anthropometric, and lifestyle factors, this relationship is lost for all morbidities, except for reduced bone mineral density, implying that INSL3 and/or its specific receptor, RXFP2, may be causally involved in promoting healthy bone metabolism. Elevated INSL3 also associates with hypertension and cardiovascular disease. When unadjusted, INSL3 in phase 1 of the EMAS study was assessed for its association with morbidity in phase 2 (mean 4.3 years later); INSL3 significantly predicts 7 out of 9 morbidity categories, behaving as well as cFT in this regard. In contrast, total T was predictive in only 3 of the 9 categories. CONCLUSION: Together with its low within-individual variance, these findings suggest that assessing INSL3 in men could offer important insight into the later development of disease in the elderly.
format Online
Article
Text
id pubmed-9679513
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96795132022-11-23 The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort Ivell, Richard Heng, Kee Severn, Katie Antonio, Leen Bartfai, Gyorgy Casanueva, Felipe F. Huhtaniemi, Ilpo T. Giwercman, Aleksander Maggi, Mario O’Connor, Daryl B. O’Neill, Terence W. Punab, Margus Rastrelli, Giulia Slowikowska-Hilczer, Jolanta Tournoy, Jos Vanderschueren, Dirk Wu, Frederick C. W. Anand-Ivell, Ravinder Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Insulin-like peptide 3 (INSL3) is a constitutive hormone secreted in men by the mature Leydig cells of the testes. It is an accurate biomarker for Leydig cell functional capacity, reflecting their total cell number and differentiation status. OBJECTIVES: To determine the ability of INSL3 to predict hypogonadism and age-related morbidity using the EMAS cohort of older community-dwelling men. MATERIALS & METHODS: Circulating INSL3 was assessed in the EMAS cohort and its cross-sectional and longitudinal relationships to hypogonadism, here defined by testosterone (T) <10.5nmol/l, and a range of age-related morbidities determined by correlation and regression analysis. RESULTS & DISCUSSION: While INSL3 is an accurate measure of primary hypogonadism, secondary and compensated hypogonadism also indicate reduced levels of INSL3, implying that testicular hypogonadism does not improve even when LH levels are increased, and that ageing-related hypogonadism may combine both primary and secondary features. Unadjusted, serum INSL3, like calculated free testosterone (cFT), LH, or the T/LH ratio reflects hypogonadal status and is associated with reduced sexual function, bone mineral density, and physical activity, as well as increased occurrence of hypertension, cardiovascular disease, cancer, and diabetes. Using multiple regression analysis to adjust for a range of hormonal, anthropometric, and lifestyle factors, this relationship is lost for all morbidities, except for reduced bone mineral density, implying that INSL3 and/or its specific receptor, RXFP2, may be causally involved in promoting healthy bone metabolism. Elevated INSL3 also associates with hypertension and cardiovascular disease. When unadjusted, INSL3 in phase 1 of the EMAS study was assessed for its association with morbidity in phase 2 (mean 4.3 years later); INSL3 significantly predicts 7 out of 9 morbidity categories, behaving as well as cFT in this regard. In contrast, total T was predictive in only 3 of the 9 categories. CONCLUSION: Together with its low within-individual variance, these findings suggest that assessing INSL3 in men could offer important insight into the later development of disease in the elderly. Frontiers Media S.A. 2022-11-08 /pmc/articles/PMC9679513/ /pubmed/36425465 http://dx.doi.org/10.3389/fendo.2022.1016107 Text en Copyright © 2022 Ivell, Heng, Severn, Antonio, Bartfai, Casanueva, Huhtaniemi, Giwercman, Maggi, O’Connor, O’Neill, Punab, Rastrelli, Slowikowska-Hilczer, Tournoy, Vanderschueren, Wu and Anand-Ivell https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Ivell, Richard
Heng, Kee
Severn, Katie
Antonio, Leen
Bartfai, Gyorgy
Casanueva, Felipe F.
Huhtaniemi, Ilpo T.
Giwercman, Aleksander
Maggi, Mario
O’Connor, Daryl B.
O’Neill, Terence W.
Punab, Margus
Rastrelli, Giulia
Slowikowska-Hilczer, Jolanta
Tournoy, Jos
Vanderschueren, Dirk
Wu, Frederick C. W.
Anand-Ivell, Ravinder
The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort
title The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort
title_full The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort
title_fullStr The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort
title_full_unstemmed The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort
title_short The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort
title_sort leydig cell biomarker insl3 as a predictor of age-related morbidity: findings from the emas cohort
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679513/
https://www.ncbi.nlm.nih.gov/pubmed/36425465
http://dx.doi.org/10.3389/fendo.2022.1016107
work_keys_str_mv AT ivellrichard theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT hengkee theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT severnkatie theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT antonioleen theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT bartfaigyorgy theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT casanuevafelipef theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT huhtaniemiilpot theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT giwercmanaleksander theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT maggimario theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT oconnordarylb theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT oneillterencew theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT punabmargus theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT rastrelligiulia theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT slowikowskahilczerjolanta theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT tournoyjos theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT vanderschuerendirk theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT wufrederickcw theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT anandivellravinder theleydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT ivellrichard leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT hengkee leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT severnkatie leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT antonioleen leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT bartfaigyorgy leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT casanuevafelipef leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT huhtaniemiilpot leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT giwercmanaleksander leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT maggimario leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT oconnordarylb leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT oneillterencew leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT punabmargus leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT rastrelligiulia leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT slowikowskahilczerjolanta leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT tournoyjos leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT vanderschuerendirk leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT wufrederickcw leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort
AT anandivellravinder leydigcellbiomarkerinsl3asapredictorofagerelatedmorbidityfindingsfromtheemascohort